Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes indeed. My guess is that the high vol PreMkt activity yesterday filled most of the gap and that the MMs may be satisfied with that. We shall see. For now the MMs seem to be okay with the PPS at +$2.
$Multi-Billion Fds investors can be Institutional, Mutual, and Hedge. So who cares. For certain $ONCS PD couldn't care less.
Agree as it is obvious. However with the dramatic news break and the jump up as they do not count the PreMkt activity, it looks like the MMs may be okay to let $ONCS move on for now.
TJ is there any more gap filling that $ONCS PPS needs to do before going up. Are the MM's satisfied?
Add the remaining $11 mil from the Cash accounts receivables and $VCEL COH becomes $36 mil. $VCEL at the CC call said that they are actively pursuing now collecting all of the remaining cash owed.
$ONCS just graduated from the NASDAQ cesspool and now has big Institutional interest.
Merck has been taking its sweet time regarding an $ONCS Partnership and that is exactly why Dan O'Connor has been hired to speed up Partnerships discussions with not only Merck but other BPs with anti-Pd1/PD-L1 FDA approved Drugs.
Waitforit53 In my direct BP experience in contract/partnership deals, BP want human clinical proven tech now, namely EP+IL12 Melanoma etc. and are more than willing to take a package where future Pre-Clinical promising tech is included in the contract/partnership package.
Also other anti-PD1/PD-L1 BPs could contact $ONCS for a Partnership deal.
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017OncoSec's Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer AgentsOncoSec Presents Emerging Preclinical Data Demonstrating its Novel Platform at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
PR NEWSWIRE 8:00 AM ET 11/9/2017
Symbol Last Price Change
ONCS 1.96down -0.04 (-2%)
QUOTES AS OF 10:15:14 AM ET 11/09/2017
SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") , a company developing DNA-based cancer immunotherapies, will present emerging data from its novel, multi-gene expression platform termed Polycistronic Interleukin-12 Immune Modulator (PIIM). The poster presentation entitled: "Intratumoral administration of a multigene construct by electroporation can effectively modulate anti-tumor response in a murine B16.F10 model" (P403) will be presented during the "Oncolytic Viruses and Intratumoral Therapies" session on Friday, November 10th at 12:30-2:00 p.m and 6:30-8:00 p.m. ET at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017, in National Harbor, MD.
The PIIM platform builds upon OncoSec's existing plasmid-based cancer immunotherapy platform and may offer both enhanced therapeutic activity as well as manufacturing efficiencies. Preclinical data demonstrate the novel platform's flexibility to add multiple immune modulating genes to alter the tumor microenvironment which, when combined with electroporation in a preclinical tumor animal model, resulted in regression of tumor growth in both the treated primary lesion and a distant untreated lesion.
"Immunotherapy has transformed the treatment of multiple cancers, including melanoma; however, current agents do not help all patients or have toxic side effects preventing broader use or in combination with other agents," said Dan O'Connor, CEO of OncoSec. "The ability to enhance response with a simultaneous and potentially safe combination therapy, including cytokines, checkpoint modulators, and antibodies, allows the immune system to better recognize and attack the tumor, an advantage of the PIIM platform versus other products currently under development."
The full abstract is available and can be viewed on the STIC website at www.sitcancer.org. The presentation is available in the Publications section of OncoSec's website.
IMO Dan would offer this new preclinical R&D tech to the BP that would Partner with $ONCS on EP+IL12 and their checkpoint inhibitor.
Dan has experience with the BPs as to negotiating Partnership and joint ventures. That is exactly why Dan was hired by $ONCS.
$ONCS has already raised cash last week with private ownership direct purchases of treasury shares.
https://www.cnbc.com/quotes/?symbol=ONCS&tab=ownership
New Insitutional owners are Anson Fund, Point72, and Intrcoastal
Yes I had previously posted on this China move to accept Clinical Trial data from other countries to award approval for the drug in China.
Hence IMO ICT will drive the approval of ALL of $VCEL drugs in China including IMO Ixcell DCM
Most definitely. China needs $VCEL as their population ages with increased diseases due to limiting 2 children per marriage.
Yes. IMO without a single doubt. $VCEL's ICT partnership will drive significant EPS revenue increases for $VCEL
$ONCS EP+IL12 is converting cold tumors into hot tumors and enabling Merck's pembrolizumab (Keytruda) to destroy the cancer for the otherwise non-responders
The small amounts of IL12 driven in via the Electroporation forced porosity of the cancerous tumors and is increasing more IL12 manufacturing inside the tumor thereby enabling aggressive patient's autologous TCell formation and destruction of the cancer.
Thxs
$ONCS P524 SITC
Conclusions P524 SITC
Most definitely, That would be $25 mil COH
Exactly 100% correct!
Dan is there for negotiation purposes period!!
Yes exactly
Thxs for that info. So it is recognized as revenue but not available as COH
Current assets:
Cash $15,466
Accounts receivable (net of allowance for doubtful accounts of $226 and $225, respectively) $15,430
Inventory $4,049
Other current assets $1,366
Total current assets $36,311
Property and equipment, net $3,967
Total assets $40,278
PFS Results 57% at 18 months P524 SITC
Progression free survival (PFS) rates for this
treatment were 62% at 6 months and 57% at 18
months (median PFS not reached at 24 months)
with a 48% BORR. DOR was not assessable as no
responders have progressed and no safety signals
were observed with only 2/22 grade 3 treatment-
emergent adverse events. In responding patients,
significant post-treatment increases were observed
in both the Th1-associated gene expression of
STAT4 and IL-12RB in biopsies, and frequencies of
CD8+
PD-1+
TIGIT+ and proliferating CD8+
PD-1+
peripherally. Additionally, responding patients had a
significant increase of TCR clonality in the tumors
compared to PBMCs with a reversed relationship in
non-responding patients. Spatial analysis by mIHC
revealed a significant increase of both PD-L1+ and
FoxP3+ cells <15um from CD8+ T cells in non-
responders. Exploratory analysis with Nanostring’s
IO360 Beta Version panels highlighted
underexpression of WNT2B and overexpression of
MICB in the pretreatment responder biopsies.
Conclusions
Durable responses and favorable PFS rates in likely
PD-1 non responders continues to suggest that
combination IT-TAVO-EP with pembrolizumab is an
effective therapeutic modality with an excellent
safety profile. Associated biomarker data highlights
connected immunological mechanisms, whereby
intratumoral Th1-polarization, associated TCR
clonality and limited suppressive cell types can drive
robust anti-tumor responses (intratumoral and
systemic) that positively impact this difficult to treat
patient population.
Trial Registration
NCT02493361
$ONCS NCT02493361
https://clinicaltrials.gov/ct2/show/NCT02493361?cond=NCT02493361&ran
https://higherlogicdownload.s3.amazonaws.com/SITCANCER/3bcb5ebf-803a-42fe-83b6-0773bc4eb962/UploadedImages/Annual%20Meeting%202017/SITC_2017_Abstract_Book.pdf
Page 585 and 586
Oncolytic Viruses and Intratumoral
Therapies
P524
Clinical and biomarker analyses of a phase II study
of intratumoral tavokinogene telseplasmid (pIL-12)
plus pembrolizumab in stage III/IV melanoma
patients predicted to not respond to anti-PD-1
Alain P. Algazi1
, Katy K. Tsai1
, Michael D.
Rosenblum1
, Robert Andtbacka2
, Carmen
Ballesteros-Merino3
, Shawn Jensen3
, Carlo B.
Bifulco3
, Bernard A. Fox3
, SuFey Ong4
, Alessandra
Cesano4
, Joseph Beechem4
, Chris Twitty5*, Jean S.
Campbell5
, Erica Browning5
, Reneta Talia5
, Shawna
A. Shirley5
, Mai H. Le5
, Robert H. Pierce5
, Sharron
Gargosky5
, Adil I. Daud1
1
University of California, Oakland, CA, USA 2
University of Utah, Salt Lake City, UT, USA
3
Providence Portland Medical Center, Portland, OR,
USA
4
NanoString Technologies, Inc., Seattle, WA, USA 5
OncoSec Medical Incorporated, San Diego, CA, USA
Background
Melanoma patients with a low frequency of PD-
1hiCTLA-4hi TIL are predicted to not respond to
pembrolizumab, yet our previous interim analysis
demonstrated that the combination of intratumoral
(IT) plasmid IL-12 (tavokinogene telseplasmid;
TAVO) and pembrolizumab yields robust clinical
responses with an excellent safety profile. Updated
clinical analyses (locked August 2017) from this
multi-center, phase II, open-label trial including 2-
year progression free survival (PFS) and DOR are
presented. New biomarker data reveals coordinated
anti-tumor immunological mechanisms in both the
tumor microenvironment (TME) and in the
peripheral blood.
Methods
Melanoma stage III/IV patients with a low CD8+ TIL
status (<25% PD-1hiCTLA-4hi)were treated with
pembrolizumab (200mg every 3 weeks)
concurrently with electroporation of IT-TAVO on
days 1, 5 and 8 (6 week cycles). Tumor samples
were profiled with multispectral
immunohistochemistry (mIHC) and NanoString’s
Human Immunology and the PanCancer IO360 Beta
Version panels. PBMC were analyzed for immune
phenotype (flow cytometry) as well as NanoString’s
PanCancer Immune Profiling RNA and Protein
panels.
Results
Progression free survival (PFS) rates for this
treatment were 62% at 6 months and 57% at 18
months (median PFS not reached at 24 months)
with a 48% BORR. DOR was not assessable as no
responders have progressed and no safety signals
were observed with only 2/22 grade 3 treatment-
emergent adverse events. In responding patients,
significant post-treatment increases were observed
in both the Th1-associated gene expression of
STAT4 and IL-12RB in biopsies, and frequencies of
CD8+
PD-1+
TIGIT+ and proliferating CD8+
PD-1+
peripherally. Additionally, responding patients had a
significant increase of TCR clonality in the tumors
compared to PBMCs with a reversed relationship in
non-responding patients. Spatial analysis by mIHC
revealed a significant increase of both PD-L1+ and
FoxP3+ cells <15um from CD8+ T cells in non-
responders. Exploratory analysis with Nanostring’s
IO360 Beta Version panels highlighted
underexpression of WNT2B and overexpression of
MICB in the pretreatment responder biopsies.
Conclusions
Durable responses and favorable PFS rates in likely
PD-1 non responders continues to suggest that
combination IT-TAVO-EP with pembrolizumab is an
effective therapeutic modality with an excellent
safety profile. Associated biomarker data highlights
connected immunological mechanisms, whereby
intratumoral Th1-polarization, associated TCR
clonality and limited suppressive cell types can drive
robust anti-tumor responses (intratumoral and
systemic) that positively impact this difficult to treat
patient population.
Trial Registration
NCT02493361
P524
Oncolytic Viruses and Intratumoral Therapies
Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1
Alain P. Algazi1, Katy K. Tsai1, Michael D. Rosenblum1, Robert Andtbacka2, Carmen Ballesteros-Merino3, Shawn Jensen3, Carlo B. Bifulco3, Bernard A. Fox3, SuFey Ong4, Alessandra Cesano4, Joseph Beechem4, Chris Twitty5, Jean S. Campbell5, Erica Browning5, Reneta Talia5, Shawna A. Shirley5, Mai H. Le5, Robert H. Pierce5, Sharron Gargosky5, Adil I. Daud1
1University of California 2University of Utah 3Providence Portland Medical Center 4NanoString Technologies, Inc. 5OncoSec Medical Incorporated
Tumor microenvironment | Biomarkers | Checkpoint blockade | Clinical study | Immune monitoring | Clinical trial | Cytokine | Tumor infiltrating lymphocytes (TILs) | Gene expression | Tumor strom
https://www.sitcancer.org/2017/abstracts/titles/late-breaking
Excellent!
Total nonsense. The Dhillons have him shackled and on a very limited leash.
Any shareholder with +5% will need to file a SC 13G
That is correct.
$ONCS Institutional + Major Insiders + Mutual Fds Holdings = +25%
https://www.cnbc.com/quotes/?symbol=ONCS&tab=ownership
Yes indeed $2.20s!!!!
Dr. Avtar Dhillon is Punit's Uncle. There are other Dhillon family members involved in the investments.
Cohen is very shrewd and knows exactly what the situation is with O'Connor.
Yes I know. They have no idea on the tight shackles that the two co-founder Dhillon brothers apply.
That is right. In name only. He is there for only one reason ..his lawyering skills in contract negotiation.
Without a doubt.
O'Connor is the new CEO for only one reason. To use his lawyering skills and finalize a contract Partnership with Merck. Otherwise O'Connor will be completely shackled from any other CEO activity.
The two co-founders Avtar and Punit Dhillon on the BOD run a tight ship and there is no way that they would let O'Connor do anything else
It is not counted as revenues until it is received.